The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Wednesday broker round-up - UPDATE

Wed, 03rd Oct 2012 09:06

African Barrick Gold: Westhouse Secuirites raises target from 464p to 495p.AG Barr: Panmure Gordon keeps hold rating and 440p target.AstraZeneca: Panmure Gordon downgrades from buy to hold, target cut from 3,100p to 3,000p.Barclays: UBS downgrades from buy to neutral, 235p target unchanged.British Sky Broadcasting: Morgan Stanley ups target from 790p to 827p, overweight rating kept.Britvic: Panmure Gordon keeps hold rating.BTG: Jefferies keeps hold recommendation and 360p target; Panmure Gordon raises target from 328p to 400p, hold rating kept; finnCap upgrades to hold.Centrica: Citigroup upgrades to buy, target lifted from 315p to 360p.Daily Mail & General Trust: Citigroup ups target from 495p to 585p, buy rating kept.Dunelm: Seymour Pierce keeps buy rating and 640p target; Panmure Gordon ups target from 700p to 720p, buy rating kept.easyJet: Panmure Gordon keeps buy rating and 650p target; ombre ups target from 580p to 650p, buy rating kept.Fidessa: Panmure Gordon cuts target from 1,459p to 1,352p, hold rating kept.FirstGroup: Jefferies reiterates hold rating and 270p target; Panmure Gordon cuts target from 280p to 230p, hold rating kept; Oriel Securities downgrades to hold.Gemfields: JPMorgan Cazenove ups target from 44p to 50p, overweight rating kept.Glencore: UBS upgrades from neutral to buy, target lifted from 390p to 420p. Hays: Oriel Securities downgrades to hold.ITV: Nomura keeps buy rating and 115p target.KCOM Group: Oriel Securities downgrades to hold.Lamprell: Investec cuts target from 100p to 55p, hold rating kept.Lloyds: UBS downgrades from buy to neutral, target lifted from 44p to 50p.Marston's: Jefferies keeps buy rating and 135p target; Panmure Gordon keeps buy rating and 130p target; Nomura keeps buy rating and 116p target.Morgan Crucible: Citigroup cuts target from 330p to 325p, buy rating kept.Rightmove: Panmure Gordon keeps buy rating and 2,000p target.Sainsbury's: Seymour Pierce retains hold rating and 310p target; Panmure Gordon keeps buy rating and 400p target; Jefferies keeps hold rating and 310p target.Schroders: UBS downgrades from neutral to sell, target lifted from 1,330p to 1,470p.Severn Trent: JPMorgan Cazenove cuts target from 1,640p to 1,610p, neutral rating kept.Smith & Nephew: Morgan Stanley downgrades to equal weight, target lifted from 660p to 969p.Sportingbet: Panmure Gordon keeps buy rating and 61p target.Tesco: Seymour Pierce reiterates reduce rating and 310p target; Jefferies keeps buy rating and 400p target; Panmure Gordon keeps buy rating and 440p target; Nomura keeps buy rating and 430p target.Virgin Media: Espirito Santo ups target from 2,880p to 3,150p, buy rating kept.WH Smith: Citigroup raises target from 660p to 720p, buy rating kept.Wolseley: Credit Suisse ups target from 2,850p to 3,000p, outperform rating kept.Xstrata: UBS upgrades from neutral to buy, target raised from 1,120p to 1,220p.BC

Related Shares

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...

29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe a...

29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.